• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    Chronic Obstructive Pulmonary Disease Market Research Report - Forecast till 2032 Infographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Chronic Obstructive Pulmonary Disease (COPD) Market

    ID: MRFR/Pharma/1081-HCR
    90 Pages
    Rahul Gotadki
    September 2025

    Chronic obstructive pulmonary disease (COPD) Market Research Report Information By CPOD Type (Emphysema, Chronic Bronchitis), By Treatment Type (Drugs, Anti-Inflammatory Drugs, Surgery, Oxygen Therapy), By End Users (Hospitals & Clinics, Homecare Settings, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Chronic Obstructive Pulmonary Disease Market Research Report - Forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Chronic Obstructive Pulmonary Disease (COPD) Market Summary

    As per Market Research Future Analysis, the Chronic Obstructive Pulmonary Disease (COPD) market was valued at USD 20.84 billion in 2023 and is projected to reach USD 33.72 billion by 2032, growing at a CAGR of 4.82% from 2024 to 2032. The rise in COPD prevalence globally, increased adoption of effective combination therapies, and heightened public awareness are key drivers of market growth. The market is also supported by rising healthcare spending in developing nations and increased R&D investments by governments and companies. The primary treatment focus remains on symptom management, with a critical need for innovative therapies targeting the disease's root causes.

    Key Market Trends & Highlights

    The COPD market is witnessing significant growth due to various factors.

    • COPD is the third leading cause of death globally, accounting for 3.23 million deaths in 2022.
    • Chronic bronchitis held the majority share of the COPD treatment market in 2021 due to rising cigarette consumption.
    • The drugs segment dominated the COPD treatment market in 2021, driven by the increasing use of medications for symptom management.
    • The Asia-Pacific region is expected to register the highest growth rate over the forecast period from 2024 to 2032.

    Market Size & Forecast

    2023 Market Size USD 20.84 Billion
    2024 Market Size USD 22.07 Billion
    2032 Market Size USD 33.72 Billion
    CAGR (2024-2032) 4.82%

    Major Players

    AstraZeneca, Abbott Laboratories, Dr. Reddy’s Laboratories Ltd, GlaxoSmithKline, F. Hoffmann-La Roche Ltd, Almirall, Boehringer Ingelheim, Pfizer Inc., Novartis AG, Astellas Pharma.

    Chronic Obstructive Pulmonary Disease (COPD) Market Trends

    Rise in prevalence of CPOD across the globe to boost market growth

    Chronic obstructive pulmonary disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management. Tobacco smoking could lead to COPD. The number of adults addicted to smoking has been increasing across the globe. Other risk factors include occupation and indoor air pollution. According to the World Health Organization (WHO), the primary cause of COPD is exposure to tobacco smoke. 

    According to the organization, chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.23 million deaths in 2022. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC).

    According to a report by the Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2022, the prevalence and burden of COPD are projected to increase in the near future due to continued exposure to COPD risk factors, rise in the incidence of interstitial lung diseases, and aging population across the world. 

    This is anticipated to augment the Chronic Obstructive Pulmonary Disease Treatment (COPD) market in the near future. The graph that follows illustrates the crude and weighted prevalence of COPD, overall and in men and women. Age-specific prevalence of COPD in men and women. Bars represent the prevalence and error bars the 95% clinical informatics.

    The Global Chronic Obstructive Pulmonary Disease (COPD) Market is poised for growth as advancements in treatment options and increased awareness of the disease's impact on public health drive demand for innovative therapies and management strategies.

    U.S. Department of Health and Human Services

    Chronic Obstructive Pulmonary Disease (COPD) Market Drivers

    Rising Prevalence of COPD

    The Global Chronic Obstructive Pulmonary Disease (COPD) Market Industry is experiencing growth due to the increasing prevalence of COPD worldwide. According to health statistics, millions of individuals are diagnosed with COPD each year, with the World Health Organization estimating that COPD will become the third leading cause of death globally by 2030. This alarming trend is prompting healthcare systems to allocate more resources towards COPD management and treatment, thereby expanding the market. The anticipated market value of 22.1 USD Billion in 2024 reflects this growing concern, as governments and organizations strive to improve patient outcomes and reduce the burden of this chronic disease.

    Market Segment Insights

    Chronic Obstructive Pulmonary Disease Treatment (COPD) Type Insights

    The Chronic Obstructive Pulmonary Disease Treatment (COPD) market segmentation, based on type, includes Emphysema, and Chronic Bronchitis. The chronic bronchitis segment held the majority share in 2021 in respect to the Chronic Obstructive Pulmonary Disease Treatment (COPD) market revenue. 

    This is primarily owing to the growing incidence and prevalence of chronic bronchitis worldwide due to the rise in the consumption of cigarettes and the increase in industrialization, which results in air pollution and the release of harmful gases into the environment.

    June 2022: AstraZeneca announced a plan to build a manufacturing unit in Qingdao, China, to produce its Breztri aerosol inhalant COPD treatment, which was recently added to the country’s National Reimbursement Drug List. Also, the company announced (in Chinese) during a meeting with local community officials but did not provide details on cost, scale, or completion date. Additionally, AstraZeneca said, that it would set up a regional headquarters in Qingdao and an innovation center focusing on rare diseases as part of its efforts to promote biomedical innovation in Qingdao.

    July 2021: AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been approved and granted Priority Review for the treatment of asthma by the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.

    Chronic Obstructive Pulmonary Disease Treatment (COPD) Treatment Type Insights

    The Chronic Obstructive Pulmonary Disease Treatment (COPD) market segmentation, based on treatment type, includes drugs, surgery, and oxygen therapy. The drugs segment held the majority share in 2021 in respect to the Chronic Obstructive Pulmonary Disease Treatment (COPD) market revenue. 

    This is primarily owing to the increasing use of drugs as the first line of treatment for COPD to make breathing easier by widening airways. Additionally, it is bifurcated into bronchodilator monotherapy, and anti-inflammatory drugs. Bronchodilator monotherapy further bifurcated into Short-Acting Beta2-Agonists (SABAs), Long-Acting Beta2-Agonists (LABAs), and anti-inflammatory drugs further bifurcated into oral and inhaled corticosteroids, and anti-leukotrienes.

    Moreover, the oxygen therapy market is projected to be the faster-growing segment during the forecast period, 2022-2030. This is due to the factors such as the rapid growth of the geriatric population the development of respiratory disorders, the rising prevalence of tobacco smoking, the increase in the usage of home-based oxygen therapy, and technological advancements. Hence, rising treatment of Chronic Obstructive Pulmonary Disease Treatment (COPD) positively impacts the market growth.

    Chronic Obstructive Pulmonary Disease (COPD) End User Insights

    The Chronic Obstructive Pulmonary Disease (COPD) market data has been bifurcated by surgery into hospitals & clinics, homecare settings, and others. The hospital & clinics segment dominated the market in 2021. This is primarily owing to the growing number of patients suffering from chronic respiratory diseases and rising awareness about these diseases. Furthermore, the availability of various diagnostics and treatment facilities and higher purchasing power has contributed to the segment’s growth.

    November 2021: AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for USD 270 Million. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).

    Figure 2: Chronic Obstructive Pulmonary Disease Treatment (COPD) Market, by End User, 2021 & 2030 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    News:

    Get more detailed insights about Chronic Obstructive Pulmonary Disease Market Research Report - Forecast till 2032

    Request Free Sample

    Regional Insights

    By Region, the study segments the market into North America, Europe, Asia-Pacific and Rest of the World. North America Chronic Obstructive Pulmonary Disease Treatment (COPD) held the largest market share in 2021. This is attributed to the increased investment in R&D activities to develop innovative drugs for treating diseases. 

    Also, the rise in incidence and prevalence of chronic respiratory diseases, technological advancement, growing healthcare sectors, and massive presence of leading market players are some of the major factors that boost the COPD Market in the region.

    Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 3: CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT (COPD) MARKET SHARE BY REGION 2021 (%)CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT (COPD) MARKET SHARE BY REGION 2021 (%)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe Chronic Obstructive Pulmonary Disease Treatment (COPD) market accounts for the second-largest market share due to the well-developed healthcare infrastructure and an increase in the incidence of chronic obstructive pulmonary diseases are propelling the COPD treatment market in the region. Further, the Germany Chronic Obstructive Pulmonary Disease Treatment (COPD) market held the largest market share, and the UK Chronic Obstructive Pulmonary Disease Treatment (COPD) market was the fastest growing market in the European region.

    The Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment (COPD) market is expected to grow with a significant share. This is due to the untapped chronic obstructive pulmonary disease treatment market compared to developed regions. Therefore, Asia Pacific offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the chronic obstructive pulmonary disease treatment market in the region.

    Moreover, China Chronic Obstructive Pulmonary Disease Treatment (COPD) market held the largest market share, and the India Chronic Obstructive Pulmonary Disease Treatment (COPD) market was the fastest growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2024–2032.

    Key Players and Competitive Insights

    Major market players are spending a lot of money on R&D to increase their product lines, which will help the Chronic Obstructive Pulmonary Disease Treatment (COPD) market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Chronic Obstructive Pulmonary Disease (COPD) industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

    One of the primary business strategies adopted by manufacturers in the Chronic Obstructive Pulmonary Disease Treatment (COPD) industry to benefit clients and expand the Chronic Obstructive Pulmonary Disease Treatment (COPD) market sector is to manufacture locally to reduce operating costs. In recent years, Chronic Obstructive Pulmonary Disease (COPD) has provided medicine with some of the most significant benefits.

    Alembic Pharmaceuticals Ltd. is a leading pharmaceutical company committed to develop, manufacture and market pharmaceutical products, pharmaceutical substances, and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs. In May 2022, Alembic Pharmaceuticals Ltd., a pharmaceutical company, received final approval from the US health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. 

    The approval by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.

    Key Companies in the Chronic Obstructive Pulmonary Disease (COPD) Market market include

    Industry Developments

    October 2021: Mylan Pharmaceuticals received the FDA approval for its investigational new drug application (ANDA) for Breyna. The first approved generic version of AstraZeneca's. It is also anticipated to be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).

    January 2019: CHIESI Farmaceutici S.p.A. entered into an exclusive license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. The agreement is aimed at developing innovative molecules for usage in the treatment of respiratory diseases.

    June 2022: Verona Pharma, announced the completion of the patient enrolment, with more than 800 subjects involved in its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease.

    Future Outlook

    Chronic Obstructive Pulmonary Disease (COPD) Market Future Outlook

    The Global Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow at a 5.27% CAGR from 2024 to 2035, driven by advancements in treatment options and increasing prevalence.

    New opportunities lie in:

    • Develop innovative digital health solutions for remote patient monitoring.
    • Expand access to personalized therapies through strategic partnerships.
    • Invest in research for novel biologics targeting COPD inflammation pathways.

    By 2035, the COPD market is expected to exhibit robust growth, reflecting enhanced treatment modalities and increased patient engagement.

    Market Segmentation

    Chronic Obstructive Pulmonary Disease Treatment (COPD) Type Outlook

    • Emphysema
    • Chronic Bronchitis

    Chronic Obstructive Pulmonary Disease Treatment (COPD) End User Outlook

    • Hospitals & Clinics
    • Homecare Settings
    • Others

    Chronic Obstructive Pulmonary Disease Treatment (COPD) Regional Outlook

    Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific

    Chronic Obstructive Pulmonary Disease Treatment (COPD) Treatment Type Outlook

    Drugs
    • Bronchodilator Monotherapy Short-Acting Beta2-Agonists (SABAs) Long-Acting Beta2-Agonists (LABAs)
    • Short-Acting Beta2-Agonists (SABAs)
    • Long-Acting Beta2-Agonists (LABAs)

    Report Scope

    Attribute/Metric Details
    Market Size 2023 USD 20.84 billion
    Market Size 2024 USD 22.07 billion
    Market Size 2032 USD 33.72 billion
    Compound Annual Growth Rate (CAGR) 4.82% (2024-2032)
    Base Year 2023
    Forecast Period 2024-2032
    Historical Data 2018 & 2020
    Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Type, Treatment Type, End User and Region
    Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
    Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled AstraZeneca (UK), Abbott Laboratories (US), Dr. Reddy’s Laboratories Ltd (India), GlaxoSmithKline (UK), F. Hoffmann-La Roche Ltd (Switzerland), Almirall (Spain), Boehringer Ingelheim (Germany), Pfizer Inc. (US), Novartis AG (Switzerland), Astellas Pharma (Japan)
    Key Market Opportunities Increasing demand for home care therapeutic devices
    Key Market Dynamics Rise in prevalence of CPOD across the globe Increase in adoption of more effective combination therapy

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch
    Leave a Comment

    FAQs

    How much is the Chronic Obstructive Pulmonary Disease Treatment (COPD) market?

    The Chronic Obstructive Pulmonary Disease Treatment (COPD) market is anticipated to reach USD 33.72 billion at a CAGR of 4.82% during the forecast period of 2024 to 2032

    How Big is the U.S Chronic Obstructive Pulmonary Disease Treatment (COPD) market?

    The U.S Chronic Obstructive Pulmonary Disease Treatment (COPD) market share is 35-40% during the forecast period of 2024 to 2032

    What is the growth rate of the Chronic Obstructive Pulmonary Disease Treatment (COPD) market?

    The Chronic Obstructive Pulmonary Disease Treatment (COPD) market is expected to register a CAGR of 4.82% during the forecast period of 2024 to 2032.

    Which region held the largest market share in the Chronic Obstructive Pulmonary Disease Treatment (COPD) market?

    The North America held the largest market share in the Chronic Obstructive Pulmonary Disease Treatment (COPD) market

    Who are the key players in the Chronic Obstructive Pulmonary Disease Treatment (COPD) market?

    AstraZeneca (UK), Abbott Laboratories (US), Dr. Reddy’s Laboratories Ltd (India), GlaxoSmithKline (UK), and F. Hoffmann-La Roche Ltd (Switzerland)

    Which treatment type led the Chronic Obstructive Pulmonary Disease Treatment (COPD) market?

    The drugs segment led the Chronic Obstructive Pulmonary Disease Treatment (COPD) market

    Which end user had the largest market share in the Chronic Obstructive Pulmonary Disease Treatment (COPD) market?

    The Hospitals & Clinics end user led the Chronic Obstructive Pulmonary Disease Treatment (COPD) market

    1. REPORT PROLOGUE
    2. MARKET INTRODUCTION
    3. Definition
      1. Scope of the Study
        1. Research Objective
    4. Assumptions
      1. Limitations
    5. RESEARCH METHODOLOGY
      1. Overview
      2. Primary Research
      3. Secondary Research
      4. Market Size Estimation
    6. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    7. MARKET FACTOR ANALYSIS
      1. Porter’s Five
    8. Forces Analysis
      1. Bargaining Power of Suppliers
        1. Bargaining
    9. Power of Buyers
      1. Threat of New Entrants
        1. Threat of Substitutes
        2. Intensity of Rivalry
      2. Value Chain Analysis
    10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE
    11. Overview
      1. Emphysema
    12. Market Estimates & Forecast, by Region, 2020-2027
    13. Market Estimates & Forecast, by Country, 2020-2027
      1. Chronic Bronchitis
    14. Market Estimates & Forecast, by Region, 2020-2027
    15. Market Estimates &
    16. Forecast, by Country, 2020-2027
    17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    18. (COPD) MARKET, BY TREATMENT TYPE
      1. Overview
      2. Drugs
    19. Market
    20. Estimates & Forecast, by Region, 2020-2027
    21. Market Estimates & Forecast,
    22. by Country, 2020-2027
      1. Bronchodilator Monotherapy
    23. Market Estimates
    24. & Forecast, by Region, 2020-2027
    25. Market Estimates & Forecast, by Country,
      1. Short-Acting Beta2-Agonists (SABAs)
    26. Market Estimates
    27. & Forecast, by Region, 2020-2027
    28. Market Estimates & Forecast, by Country,
      1. Long-Acting Beta2-Agonists (LABAs)
    29. Market Estimates
    30. & Forecast, by Region, 2020-2027
    31. Market Estimates & Forecast, by Country,
      1. Anti-Drugs Agent
    32. Market Estimates & Forecast, by
    33. Region, 2020-2027
    34. Market Estimates & Forecast, by Country, 2020-2027
      1. Anti-Inflammatory Drugs
    35. Market Estimates & Forecast, by Region,
    36. Market Estimates & Forecast, by Country, 2020-2027
    37. Oral and Inhaled Corticosteroids
    38. Market Estimates & Forecast, by Region,
    39. Market Estimates & Forecast, by Country, 2020-2027
    40. Anti-Leukotrienes
    41. Market Estimates & Forecast, by Region, 2020-2027
    42. Market Estimates & Forecast, by Country, 2020-2027
      1. Surgery
    43. Market
    44. Estimates & Forecast, by Region, 2020-2027
    45. Market Estimates & Forecast,
    46. by Country, 2020-2027
      1. Lung Volume Reduction Surgery (LVRS)
    47. Market
    48. Estimates & Forecast, by Region, 2020-2027
    49. Market Estimates & Forecast,
    50. by Country, 2020-2027
      1. Lung Transplant
    51. Market Estimates & Forecast,
    52. by Region, 2020-2027
    53. Market Estimates & Forecast, by Country, 2020-2027
      1. Bullectomy
    54. Market Estimates & Forecast, by Region, 2020-2027
    55. Market Estimates & Forecast, by Country, 2020-2027
      1. Others
    56. Market
    57. Estimates & Forecast, by Region, 2020-2027
    58. Market Estimates & Forecast,
    59. by Country, 2020-2027
      1. Oxygen Therapy
    60. Market Estimates & Forecast,
    61. by Region, 2020-2027
    62. Market Estimates & Forecast, by Country, 2020-2027
    63. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER
      1. Overview
      2. Hospitals and Clinics
    64. Market Estimates & Forecast,
    65. by Region, 2020-2027
    66. Market Estimates & Forecast, by Country, 2020-2027
      1. Homecare Settings
    67. Market Estimates & Forecast, by Region, 2020-2027
    68. Market Estimates & Forecast, by Country, 2020-2027
      1. Others
    69. Market
    70. Estimates & Forecast, by Region, 2020-2027
    71. Market Estimates & Forecast,
    72. by Country, 2020-2027
    73. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    74. MARKET, BY REGION
      1. Overview
      2. Americas
        1. North America
        2. Latin America
      3. Europe
        1. Western Europe
    75. Italy
      1. Spain
        1. UK
        2. Eastern Europe
      2. Asia-Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. South Korea
        6. Rest of
    76. Asia-Pacific
      1. Middle East & Africa
        1. Middle East
    77. Africa
    78. COMPANY LANDSCAPE
      1. Overview
      2. Competitive Analysis
      3. Market Share Analysis
      4. Major Growth Strategy in the Global Chronic
    79. Obstructive Pulmonary Disease (COPD) Market
      1. Competitive Benchmarking
      2. Leading Players in Terms of the Number of Developments in the Global Chronic
    80. Obstructive Pulmonary Disease (COPD) Market
      1. Key Developments and Growth
    81. Strategies
      1. Product Launch/Service Deployment
        1. Mergers and
    82. Acquisitions
      1. Joint Ventures
      2. Major Players Financial Matrix
    83. & Market Ratio
      1. Sales & Operating Income 2020
        1. Major
    84. Players R&D Expenditure 2020
      1. Major Players Capital Market Ratio
    85. COMPANY PROFILES
      1. Abbott Laboratories
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key
    86. Developments
      1. SWOT Analysis
        1. Key Strategies
    87. Almirall
      1. Company Overview
        1. Product Overview
    88. Financial Overview
      1. Key Developments
        1. SWOT Analysis
        2. Key Strategies
      2. Astellas Pharma
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      3. AstraZeneca
        1. Company Overview
        2. Product Overview
        3. Financial
    89. Overview
      1. Key Developments
        1. SWOT Analysis
    90. Key Strategies
      1. Boehringer Ingelheim
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      2. Circassia Pharmaceuticals
        1. Company Overview
        2. Product Overview
        3. Financial
    91. Overview
      1. Key Developments
        1. SWOT Analysis
    92. Key Strategies
      1. GlaxoSmithKline plc
        1. Company Overview
    93. Product Overview
      1. Financial Overview
        1. Key Developments
        2. SWOT Analysis
        3. Key Strategies
      2. Novartis AG
        1. Company Overview
        2. Product Overview
        3. Financial
    94. Overview
      1. Key Developments
        1. SWOT Analysis
    95. Key Strategies
      1. Pfizer, Inc.
        1. Company Overview
    96. Product Overview
      1. Financial Overview
        1. Key Developments
        2. SWOT Analysis
        3. Key Strategies
      2. Teva Pharmaceutical
    97. Industries Ltd
      1. Company Overview
        1. Product Overview
        2. Financial Overview
        3. Key Developments
        4. SWOT
    98. Analysis
      1. Key Strategies
      2. Others
    99. APPENDIX
    100. References
      1. Related Reports
    101. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SYNOPSIS, 2020-2027
    102. FORECAST, 2020-2027 (USD MILLION)
    103. DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
    104. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027
    105. (USD MILLION)
    106. BY END USER, 2020-2027 (USD MILLION)
    107. DISEASE (COPD) MARKET, BY REGION, 2020-2027 (USD MILLION)
    108. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD
    109. MILLION)
    110. MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
    111. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD
    112. MILLION)
    113. BY COPD TYPE, 2020-2027 (USD MILLION)
    114. DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
    115. US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027
    116. (USD MILLION)
    117. MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
    118. PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
    119. 2027 (USD MILLION)
    120. DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
    121. AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE,
    122. 2027 (USD MILLION)
    123. DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
    124. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD
    125. MILLION)
    126. BY TREATMENT TYPE, 2020-2027 (USD MILLION)
    127. PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
    128. WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD
    129. TYPE, 2020-2027 (USD MILLION)
    130. PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
    131. BY END USER, 2020-2027 (USD MILLION)
    132. PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
    133. EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT
    134. TYPE, 2020-2027 (USD MILLION)
    135. PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD MILLION)
    136. ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE,
    137. 2027 (USD MILLION)
    138. DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2020-2027 (USD MILLION)
    139. ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER,
    140. 2027 (USD MILLION)
    141. PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2020-2027 (USD MILLION)
    142. MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET,
    143. BY TREATMENT TYPE, 2020-2027 (USD MILLION)
    144. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2020-2027 (USD
    145. MILLION)
    146. MARKET STRUCTURE FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET
    147. (COPD) MARKET
    148. MARKET SHARE, BY COPD TYPE, 2020 (%)
    149. DISEASE (COPD) MARKET SHARE, BY TREATMENT TYPE, 2020 (%)
    150. OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY END USER, 2020 (%)
    151. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020
    152. SHARE BY REGION, 2020 (%)
    153. DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
    154. OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)
    155. WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY
    156. COUNTRY, 2020 (%)
    157. (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
    158. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
    159. SHARE ANALYSIS, 2020 (%)
    160. REGIONAL REVENUE
    161. SEGMENTAL REVENUE
    162. PHARMA: KEY FINANCIALS
    163. ASTELLAS PHARMA: REGIONAL REVENUE
    164. REVENUE
    165. INGELHEIM: SEGMENTAL REVENUE
    166. SEGMENTAL REVENUE
    167. SEGMENTAL REVENUE
    168. NOVARTIS AG: KEY FINANCIALS
    169. REVENUE
    170. TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE
    171. INDUSTRIES LTD: REGIONAL REVENUE

    Chronic Obstructive Pulmonary Disease (COPD) Market Segmentation Chronic obstructive pulmonary disease (COPD) Type Outlook (USD Billion, 2018-2030)

    • Emphysema
    • Chronic Bronchitis

    Chronic obstructive pulmonary disease (COPD) Treatment Outlook (USD Billion, 2018-2030)

    • Drugs

      • Bronchodilator Monotherapy

        • Short-Acting Beta2-Agonists (SABAs)
        • Long-Acting Beta2-Agonists (LABAs)

      • Anti-Inflammatory Drugs

        • Oral And Inhaled Corticosteroids
        • Anti-Leukotrienes

    • Surgery

      • Lung Volume Reduction Surgery (LVRS)
      • Lung Transplant
      • Bullectomy
      • Others
    • Oxygen Therapy

    Chronic obstructive pulmonary disease (COPD) End User Outlook (USD Billion, 2018-2030)

    • Hospitals & Clinics
    • Homecare Settings
    • Others

    Chronic obstructive pulmonary disease (COPD) Regional Outlook (USD Billion, 2018-2030)

    • North America Outlook (USD Billion, 2018-2030)

      • North America Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • North America Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • North America Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • US Outlook (USD Billion, 2018-2030)

      • US Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • US Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • US Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Canada Outlook (USD Billion, 2018-2030)

      • Canada Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Canada Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Canada Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

    • Europe Outlook (USD Billion, 2018-2030)

      • Europe Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Europe Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Europe Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Germany Outlook (USD Billion, 2018-2030)

      • Germany Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Germany Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Germany Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • France Outlook (USD Billion, 2018-2030)

      • France Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • France Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • France Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • UK Outlook (USD Billion, 2018-2030)

      • UK Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • UK Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • UK Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Italy Outlook (USD Billion, 2018-2030)

      • Italy North America Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Italy Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

            • Anti-Inflammatory Drugs

              • Oral And Inhaled Corticosteroids
              • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Italy Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Spain Outlook (USD Billion, 2018-2030)

      • Spain Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Spain Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)
            •  

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Spain Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Rest Of Europe Outlook (USD Billion, 2018-2030)

      • Rest Of Europe Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Rest of Europe Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)

            • Long-Acting Beta2-Agonists (LABAs)

              Anti-Inflammatory Drugs

              • Oral And Inhaled Corticosteroids
              • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Rest of Europe Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

    • Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • China Outlook (USD Billion, 2018-2030)

      • China Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • China Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • China Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Japan Outlook (USD Billion, 2018-2030)

      • Japan Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Japan Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Japan Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • India Outlook (USD Billion, 2018-2030)

      • India Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • India Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • India Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • South Korea Outlook (USD Billion, 2018-2030)

      • South Korea Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • South Korea Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • South Korea Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Australia Outlook (USD Billion, 2018-2030)

      • Australia Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Australia Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Australia Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2030)

      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Rest of Asia-Pacific Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

    • Rest of the World Outlook (USD Billion, 2018-2030)

      • Rest of the World Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Rest of the World Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Rest of the World Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Middle East Outlook (USD Billion, 2018-2030)

      • Middle East Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Middle East Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Middle East Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Africa Outlook (USD Billion, 2018-2030)

      • Africa Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Africa Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Africa Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others

      • Latin America Outlook (USD Billion, 2018-2030)

      • Latin America Chronic obstructive pulmonary disease (COPD) by Type
        • Emphysema
        • Chronic Bronchitis
      • Latin America Chronic obstructive pulmonary disease (COPD) by Treatment

        • Metal Drugs

          • Bronchodilator Monotherapy

            • Short-Acting Beta2-Agonists (SABAs)
            • Long-Acting Beta2-Agonists (LABAs)

          • Anti-Inflammatory Drugs

            • Oral And Inhaled Corticosteroids
            • Anti-Leukotrienes

        • Surgery

          • Lung Volume Reduction Surgery (LVRS)
          • Lung Transplant
          • Bullectomy
          • Others
        • Oxygen Therapy
      • Latin America Chronic obstructive pulmonary disease (COPD) by End User
        • Hospitals & Clinics
        • Homecare Settings
        • Others
    Chronic Obstructive Pulmonary Disease Market Research Report - Forecast till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027